RT Journal Article
SR Electronic
T1 Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments
JF Disease Models & Mechanisms
JO Dis Models Mech
FD The Company of Biologists Limited
SP 727
OP 732
DO 10.1242/dmm.007724
VO 4
IS 6
A1 Draoui, Nihed
A1 Feron, Olivier
YR 2011
UL http://dmm.biologists.org/content/4/6/727.abstract
AB Hypoxia and oncogene expression both stimulate glycolytic metabolism in tumors, thereby leading to lactate production. However, lactate is more than merely a by-product of glycolysis: it can be used as a metabolic fuel by oxidative cancer cells. This phenomenon resembles processes that have been described for skeletal muscle and brain that involve what are known as cell-cell and intracellular lactate shuttles. Two control points regulate lactate shuttles: the lactate dehydrogenase (LDH)-dependent conversion of lactate into pyruvate (and back), and the transport of lactate into and out of cells through specific monocarboxylate transporters (MCTs). In tumors, MCT4 is largely involved in hypoxia-driven lactate release, whereas the uptake of lactate into both tumor cells and tumor endothelial cells occurs via MCT1. Translating knowledge of lactate shuttles to the cancer field offers new perspectives to therapeutically target the hypoxic tumor microenvironment and to tackle tumor angiogenesis.